Your browser doesn't support javascript.
loading
Second surgery for relapsed glioblastoma: an observational study on criteria for patient selection in real life.
Lecce, Mario; Rasile, Fabrizio; Tanzilli, Antonio; Gaviani, Paola; Mariantonia, Carosi; Villani, Veronica; Pace, Andrea; Terrenato, Irene; Casini, Beatrice; Novello, Mariangela; Telera, Stefano.
Afiliación
  • Lecce M; Neurosurgery Unit, IRCCS Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144, Rome, Italy.
  • Rasile F; Neurosurgery Unit, IRCCS Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144, Rome, Italy.
  • Tanzilli A; Neuro Oncology Unit Fondazione IRCSS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Gaviani P; Neuro-Oncology Unit, IRCCS Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144, Rome, Italy.
  • Mariantonia C; Pathology Unit IRCCS Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144, Rome, Italy.
  • Villani V; Neuro Oncology Unit Fondazione IRCSS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Pace A; Neuro Oncology Unit Fondazione IRCSS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Terrenato I; Clinical Trial Center & Biostatistics & Bioinformatics Unit IRCCS Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144, Rome, Italy.
  • Casini B; Pathology Unit IRCCS Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144, Rome, Italy.
  • Novello M; Pathology Unit IRCCS Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144, Rome, Italy.
  • Telera S; Neurosurgery Unit, IRCCS Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144, Rome, Italy.
Future Oncol ; : 1-9, 2024 Jun 11.
Article en En | MEDLINE | ID: mdl-38861296
ABSTRACT

Aim:

There is little consensus on salvage management of glioblastoma after recurrence, for lack of evidence. Materials & 

methods:

A retrospective study of treatments in patients with recurrent glioblastoma.

Results:

Surgery at recurrence was related to better overall survival (OS) and progression-free survival (PFS). Surgery at recurrence, Karnofsky index, MGMT methylation status, younger age at diagnosis and number of chemotherapy cycles were positive factors for OS and PFS. The benefit of OS was relevant for a second surgery performed at least 9 months after the first one. Systemic treatments after the second surgery were linked to an improved PFS.

Conclusion:

Younger age, Karnofsky index, MGMT methylation status and a median time between surgeries ≥9 months may be criteria for eligibility for surgery at recurrence.
[Box see text].
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Future Oncol Año: 2024 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Future Oncol Año: 2024 Tipo del documento: Article País de afiliación: Italia